NEW YORK (GenomeWeb) – Belgian diagnostics company MDxHealth reported before the opening of the market on Thursday that its full-year 2016 revenues rose 70 percent, driven by strong growth in its ConfirmMDx prostate cancer test and the launch of its SelectMDx liquid biopsy test.

The company reported total revenues of $30.0 million, up from $17.6 million in 2015. Of the total, US revenues rose 60 percent to $24.4 million from $15.2 million in 2015, and non-US revenues rose 133 percent to $5.6 million from $2.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.